Stejskal D, Bartek J, Pastorková R, Růzicka V, Oral I, Horalík D
Department of Laboratory Medicine and Internal Medicine, Hospital Sternberk.
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2001 Dec;145(2):61-4. doi: 10.5507/bp.2001.013.
Osteoprotegerin, RANK (Receptor Activator of Nuclear factor kappa B) and RANKL (Receptor Activator of Nuclear faktor kappa B ligand) became the aim of intensive research. RANK is considered as a hematopoietic surface receptor controlling osteoclastogenesis and calcium metabolism. RANKL may promote osteoresorption by induction of cathepsin K gene expression. The present paper summarizes the most significant data in osteoprotegerin, RANK and RANKL problems obtained.
骨保护素、核因子κB受体激活剂(RANK)和核因子κB受体激活剂配体(RANKL)成为了深入研究的目标。RANK被认为是一种控制破骨细胞生成和钙代谢的造血表面受体。RANKL可能通过诱导组织蛋白酶K基因表达来促进骨吸收。本文总结了在骨保护素、RANK和RANKL问题上获得的最重要的数据。